Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Amyloid Fibrils

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A Ru(ii)-arene complex with promising anti-Aβ activity.

RSC advances·2026

Same author

Synthesis of Phenaliporphyrin, a PAH-Porphyrin Hybrid, from an Acenaphthene-Fused Cyclopropane Dialdehyde.

The Journal of organic chemistry·2025

Same author

Evolution of spinal evoked compound action potential thresholds, visual motor thresholds, and impedances in a rodent spared nerve injury model.

Frontiers in neuroscience·2025

Same author

Ruthenium(II)-Arene Complexes with a 2,2'-Bipyridine Ligand as Anti-Aβ Agents.

Biomolecules·2025

Same author

Inhibitory Effects of Sulfur Derivatives on <i>Leishmania tarentolae</i> Cell Viability and Secreted Acid Phosphatase In Vitro.

Microorganisms·2025

Same author

Ru(II)-arene azole complexes as anti-amyloid-β agents.

Dalton transactions (Cambridge, England : 2003)·2024

Search research articles

Related Experiment Video

Updated: Oct 5, 2025

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

A Dual-Pronged Approach: A Ruthenium(III) Complex That Modulates Amyloid-β Aggregation and Disrupts Its Formed

Gideon K Yawson¹, Mark F Will¹, Samantha E Huffman¹

¹Department of Chemistry, Illinois State University, Normal, Illinois 61790-4160, United States.

Inorganic Chemistry

|February 1, 2022

Summary

This summary is machine-generated.

Researchers developed novel ruthenium complexes to target amyloid-beta (Aβ) aggregation in Alzheimer's disease (AD). A lead compound, Oc, effectively modulated Aβ aggregation and reduced its toxicity, offering a new therapeutic strategy.

More Related Videos

The Synthesis, Characterization and Reactivity of a Series of Ruthenium N-triphosPh Complexes

The Synthesis, Characterization and Reactivity of a Series of Ruthenium N-triphosPh Complexes

Published on: April 10, 2015

Synthesis and Evaluation of a Ruthenium-based Mitochondrial Calcium Uptake Inhibitor

Synthesis and Evaluation of a Ruthenium-based Mitochondrial Calcium Uptake Inhibitor

Published on: October 26, 2017

Related Experiment Videos

Last Updated: Oct 5, 2025

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

The Synthesis, Characterization and Reactivity of a Series of Ruthenium N-triphosPh Complexes

The Synthesis, Characterization and Reactivity of a Series of Ruthenium N-triphosPh Complexes

Published on: April 10, 2015

Synthesis and Evaluation of a Ruthenium-based Mitochondrial Calcium Uptake Inhibitor

Synthesis and Evaluation of a Ruthenium-based Mitochondrial Calcium Uptake Inhibitor

Published on: October 26, 2017

Area of Science:

Neuroscience
Chemistry
Drug Discovery

Background:

Alzheimer's disease (AD) is linked to neurotoxic amyloid-beta (Aβ) oligomers.
Metal-based therapeutics, particularly ruthenium (Ru) complexes, show promise for targeting Aβ.
Previous azole-based Ru(III) complexes modulated Aβ aggregation, with primary amines enhancing activity.

Purpose of the Study:

To synthesize and evaluate novel oxazole-based Ru complexes for modulating Aβ aggregation.
To identify a lead compound with superior activity against Aβ toxicity.
To explore new therapeutic strategies for Alzheimer's disease.

Main Methods:

Synthesis of a series of oxazole-based ruthenium complexes.
In vitro evaluation of complex activity in modulating Aβ aggregation.
Assessment of cytotoxicity of Aβ in the presence of the complexes.
Analysis of the effect of the lead compound on pre-formed Aβ aggregates.

Main Results:

A lead compound, Oc, demonstrated superior activity in modulating soluble Aβ aggregation compared to previous azole-based complexes.
Oc effectively diminished Aβ-induced cytotoxicity.
Oc was shown to disrupt pre-formed Aβ aggregates into smaller amorphous species.

Conclusions:

Oxazole-based ruthenium complexes represent a promising class of therapeutic agents for Alzheimer's disease.
The lead compound Oc offers a novel dual approach by modulating both Aβ aggregation and disrupting existing aggregates.
This work opens new avenues for developing effective metal-based treatments for Alzheimer's disease.